115 related articles for article (PubMed ID: 37290996)
61. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
62. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
[TBL] [Abstract][Full Text] [Related]
63. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
64. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
65. A systematic review and meta
Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
[TBL] [Abstract][Full Text] [Related]
66. Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.
Cortes JE; Jonas BA; Graef T; Luan Y; Stein AS
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):509-515.e1. PubMed ID: 31227358
[TBL] [Abstract][Full Text] [Related]
67. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Bedard PL; Tabernero J; Janku F; Wainberg ZA; Paz-Ares L; Vansteenkiste J; Van Cutsem E; Pérez-García J; Stathis A; Britten CD; Le N; Carter K; Demanse D; Csonka D; Peters M; Zubel A; Nauwelaerts H; Sessa C
Clin Cancer Res; 2015 Feb; 21(4):730-8. PubMed ID: 25500057
[TBL] [Abstract][Full Text] [Related]
68. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
Visani G; Milligan D; Leoni F; Chang J; Kelsey S; Marcus R; Powles R; Schey S; Covelli A; Isidori A; Litchman M; Piccaluga PP; Mayer H; Malagola M; Pfister C
Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
[TBL] [Abstract][Full Text] [Related]
69. Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study.
Nishina T; Fujita T; Yoshizuka N; Sugibayashi K; Murayama K; Kuboki Y
BMJ Open; 2022 Oct; 12(10):e055718. PubMed ID: 36270753
[TBL] [Abstract][Full Text] [Related]
70. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Martínez Sánchez MP; Megías-Vericat JE; Rodríguez-Veiga R; Vives S; Bergua JM; Torrent A; Suárez-Varela S; Boluda B; Martínez-López J; Cano-Ferri I; Acuña-Cruz E; Torres-Miñana L; Martín-Herreros B; Serrano A; Sempere A; Barragán E; Sargas C; Sanz M; Martínez-Cuadrón D; Montesinos P;
Ann Hematol; 2021 Jun; 100(6):1497-1508. PubMed ID: 33914097
[TBL] [Abstract][Full Text] [Related]
71. Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.
Ikezoe T; Ando K; Onozawa M; Yamane T; Hosono N; Morita Y; Kiguchi T; Iwasaki H; Miyamoto T; Matsubara K; Sugimoto S; Miyazaki Y; Kizaki M; Akashi K
Cancer Sci; 2022 Dec; 113(12):4258-4266. PubMed ID: 35689544
[TBL] [Abstract][Full Text] [Related]
72. The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma.
Raab MS; Thomas SK; Ocio EM; Guenther A; Goh YT; Talpaz M; Hohmann N; Zhao S; Xiang F; Simon C; Vanasse KG; Kumar SK
Leukemia; 2019 Dec; 33(12):2924-2933. PubMed ID: 31092894
[TBL] [Abstract][Full Text] [Related]
73. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
74. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB
Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
[TBL] [Abstract][Full Text] [Related]
75. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.
Swords RT; Greenberg PL; Wei AH; Durrant S; Advani AS; Hertzberg MS; Jonas BA; Lewis ID; Rivera G; Gratzinger D; Fan AC; Felsher DW; Cortes JE; Watts JM; Yarranton GT; Walling JM; Lancet JE
Leuk Res; 2016 Nov; 50():123-131. PubMed ID: 27736729
[TBL] [Abstract][Full Text] [Related]
76. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B
Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119
[TBL] [Abstract][Full Text] [Related]
77. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
[TBL] [Abstract][Full Text] [Related]
78. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
Kenealy M; Patton N; Filshie R; Nicol A; Ho SJ; Hertzberg M; Mills T; Prosser I; Link E; Cowan L; Zannino D; Seymour JF
Leuk Lymphoma; 2017 Feb; 58(2):298-307. PubMed ID: 27268068
[TBL] [Abstract][Full Text] [Related]
79. A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Zeidan AM; Ridinger M; Lin TL; Becker PS; Schiller GJ; Patel PA; Spira AI; Tsai ML; Samuëlsz E; Silberman SL; Erlander M; Wang ES
Clin Cancer Res; 2020 Dec; 26(23):6132-6140. PubMed ID: 32998961
[TBL] [Abstract][Full Text] [Related]
80. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.
Cortes J; Tamura K; DeAngelo DJ; de Bono J; Lorente D; Minden M; Uy GL; Kantarjian H; Chen LS; Gandhi V; Godin R; Keating K; McEachern K; Vishwanathan K; Pease JE; Dean E
Br J Cancer; 2018 May; 118(11):1425-1433. PubMed ID: 29765150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
